Anifrolumab 是一种 I 型干扰素 (IFN) 受体拮抗剂，是一种人源单克隆抗体。Anifrolumab 能阻断 I 型干扰素的活性，可用于系统性红斑狼疮 (SLE) 的研究。

Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research.

Liquid

Anifrolumab (67.7?nM; 20 min) induces sustained reduction of surface IFNAR1 and abrogates STAT1 phosphorylation.
Anifrolumab (1 and 10 μg/mL; 6 or 7 d) suppresses differentiation of B cells into plasma cells.
Anifrolumab inhibits type I IFN-induced ISRE signaling, with IC50s ranging from 0.004 to 0.3?nM for the IFN-α subtypes, and 0.03?nM and 0.07?nM for IFN-β and IFN-ω, respectively.
Anifrolumab (67.7?nM) dose-dependently inhibits IFN-α production from pDCs in response to CpG-A or DNA-IC stimulation, inhibiting 87-95% of IFN-α production. has not independently confirmed the accuracy of these methods. They are for reference only.

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

[1]. Furie R, et al. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. Arthritis Rheumatol. 2017 Feb;69(2):376-386.
[2]. Riggs JM, et al. Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci Med. 2018 Apr 5;5(1):e000261.